1262992-43-7

• 常用中文名：Rifaximin-d6
• 常用英文名：Rifaximin-d6
• CAS号：1262992-43-7
• 分子式：C₄₃H₄₅D₆N₃O₁₁
• 分子量：791.916
• 相关类别： 信号通路 抗感染 细菌
• 发布时间：2021-06-09 14:51:45
• 更新时间：2024-01-10 11:27:54
• 利福昔明-d6是氘标记的利福昔明。利福昔明是一种口服、半合成、非系统性抗生素,源自利福霉素SV,具有抗菌活性[1][2]。

名称

• 英文名: Rifaximin-d6
• 英文别名: 2,7-(Epoxy[1,11,13]pentadecatrienoimino)furo[2'',3'':7',8']naphth[1',2':4,5]imidazo[1,2-a]pyridine-1,15(2H)-dione-9,10,12-d3, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,16,20,22,24,26-hept amethyl-11-(methyl-d3)-, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-Tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-30-(2H3)methyl-6,23-dioxo(28,29,31-2H3)-8,37-dioxa-24,27,33-triazahexacyclo[23 .10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl acetate; RIFAXIMIN-D6

物化性质

• 密度: 1.4±0.1 g/cm3
• 分子式: C₄₃H₄₅D₆N₃O₁₁
• 分子量: 791.916
• 精确质量: 791.390015
• LogP: 3.22
• 折射率: 1.634

生物活性

• 描述: 利福昔明-d6是氘标记的利福昔明。利福昔明是一种口服、半合成、非系统性抗生素,源自利福霉素SV,具有抗菌活性[1][2]。
• 相关类别:
  研究领域 >> 感染
  信号通路 >> 抗感染 >> 细菌
• 体外研究: 氢、碳和其他元素的稳定重同位素已被纳入药物分子,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
• 参考文献:

  [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

  [2]. Cruciani F, Brigidi P, Calanni F et al. Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota. Antimicrob Agents Chemother. 2012 Aug;56(8):4062-70.

  [3]. Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother. 2012 Feb;13(3):433-40.

  [4]. Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clin Ther. 2011 Jul;33(7):812-27.

  [5]. Cottreau J, Baker SF, DuPont HL, Garey KW. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther. 2010 Jul;8(7):747-60.

  [6]. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010 Jan;26(1):17-25.

  [7]. Ojetti V, Lauritano EC, Barbaro F et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):675-82.